• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lucid Diagnostics Expands Direct Contracting Initiative with Multiple Programs Focused on Near-Term Revenue Drivers

    11/5/24 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $LUCD alert in real time by email

    Industry veterans from leading cancer detection firm join Lucid to support expansion in fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets

    NEW YORK, Nov. 5, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that its commercial team has embarked on an expansion of its direct contracting initiative, focusing on programs designed to drive near-term EsoGuard® Esophageal DNA Test revenue, complementing ongoing efforts in traditional reimbursement. These programs include fully-contracted #CheckYourFoodTube Precancer Testing Events, Concierge Medicine, and Employer Markets. To support these initiatives, Lucid has hired two seasoned professionals from GRAIL, Inc., who have successfully driven revenue from the Galleri® multi-cancer early detection test in similar programs.

    Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device. (PRNewsfoto/Lucid Diagnostics)

    "Following the recent explosion in our clinical evidence base for EsoGuard esophageal precancer testing, our team carefully explored new opportunities to expand our commercial strategy while we also seek to leverage this data to secure traditional commercial and Medicare coverage," said Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer. "With this data in hand, we are now laser-focused on translating our test volume growth into contractually-guaranteed revenue. We are confident that we can convert our growing #CheckYourFoodTube testing events into contracted events, as we recently demonstrated at the Fort Worth Fire Department in partnership with Front Line Mobile Health. Our Employer Markets initiatives are demonstrating that brokers and self-insured entities are willing to offer EsoGuard as a covered benefit. Finally, we believe that we have the opportunity to successfully penetrate the Concierge Medicine market, just as GRAIL has done."

    Fully-Contracted #CheckYourFoodTube Precancer Testing Events

    Lucid's #CheckYourFoodTube events program will now focus on securing agreements with self-insured entities, including employers, unions, and municipal departments to drive contractually-guaranteed revenue. Recent successes in this program include Lucid's first major directly-contracted precancer testing event, where 200 Fort Worth Fire Department firefighters received EsoGuard testing in partnership with Front Line Mobile Health. Following this initial success, the Company has designated a senior member, Erica Austin, of its commercial team to focus exclusively on such contracted #CheckYourFoodTube events.

    Concierge Medicine Program

    The concierge medicine sector, which offers patients enhanced access to physicians and personalized care for an annual fee, is rapidly growing nationwide. Patients in these concierge medicine practices routinely seek access to cutting-edge technologies such as EsoGuard. Carlie Craig, Lucid's new Senior Director of Strategic Partnerships for Concierge & Executive Medicine, has extensive relationships in the concierge medicine sector and has demonstrated success at driving revenue from this sector at GRAIL and elsewhere.

    Employer Markets Program

    Over half of patients in the United States are insured under self-funded plans, including through their employers, unions, or other entities. These plans are typically established through a network of health and wellness program brokers who seek to offer their clients value-added services, such as EsoGuard esophageal precancer testing. Lisa Krause has joined Lucid as Senior Director of Employer Partnerships, bringing extensive experience from her role at GRAIL, where she successfully introduced the Galleri multi-cancer early detection test to employers and brokers.

    About Lucid Diagnostics

    Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.

    For more information about Lucid, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.

    Forward-Looking Statements

    This press release includes forward-looking statements that involve risk and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid's management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid's common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid's products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid's clinical and preclinical studies; whether and when Lucid's products are cleared by regulatory authorities; market acceptance of Lucid's products once cleared and commercialized; Lucid's ability to raise additional funding as needed; and other competitive developments. In addition, Lucid continues to monitor the COVID-19 pandemic and the pandemic's impact on Lucid's businesses. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid's control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid's future operations, see Part I, Item 1A, "Risk Factors," in Lucid's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report.  Lucid disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-expands-direct-contracting-initiative-with-multiple-programs-focused-on-near-term-revenue-drivers-302296331.html

    SOURCE Lucid Diagnostics

    Get the next $LUCD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LUCD
    $PAVM

    CompanyDatePrice TargetRatingAnalyst
    Lucid Diagnostics Inc.
    $LUCD
    12/27/2021$16.00Buy
    Ascendiant Capital
    Lucid Diagnostics Inc.
    $LUCD
    12/15/2021$17.00 → $13.00Buy
    Needham
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$18.00Buy
    Canaccord Genuity
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$14.00Buy
    BTIG Research
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$21.00Overweight
    Cantor Fitzgerald
    Lucid Diagnostics Inc.
    $LUCD
    11/8/2021$17.00Buy
    Needham
    More analyst ratings

    $LUCD
    $PAVM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PAVmed Subsidiary, Veris Health and The Ohio State University Comprehensive Cancer Center Launch Commercial Phase of Strategic Partnership Agreement

    The Veris Cancer Care Platform to be deployed to enhance personalized cancer care in patients undergoing systemic cancer therapy across OSUCCC – James NEW YORK, Oct. 7, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company") a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, and its majority-owned digital health subsidiary Veris Health Inc. ("Veris"), today announced that Veris and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), a National Cancer Institute (NCI)-Designated Comprehensive Cancer C

    10/7/25 8:01:00 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital initiated coverage on Lucid Diagnostics with a new price target

    Ascendiant Capital initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $16.00

    12/27/21 6:21:16 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Needham reiterated coverage on Lucid Diagnostics with a new price target

    Needham reiterated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $13.00 from $17.00 previously

    12/15/21 6:36:10 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Canaccord Genuity initiated coverage on Lucid Diagnostics with a new price target

    Canaccord Genuity initiated coverage of Lucid Diagnostics with a rating of Buy and set a new price target of $18.00

    11/8/21 10:16:23 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Matheis Dennis bought $101,840 worth of shares (100,000 units at $1.02), increasing direct ownership by 18% to 665,443 units (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    8/22/25 5:17:58 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Amendment: Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31), increasing direct ownership by 40% to 565,443 units (SEC Form 4)

    4/A - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/23/25 4:14:42 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Matheis Dennis bought $457,607 worth of shares (350,000 units at $1.31) (SEC Form 4)

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    5/22/25 4:45:49 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Lucid Diagnostics Inc.

    SCHEDULE 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    10/10/25 9:45:03 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Lucid Diagnostics Inc. (0001799011) (Filer)

    9/25/25 8:57:08 AM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    PAVmed Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PAVmed Inc. (0001624326) (Filer)

    9/11/25 9:28:47 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Palumbo John R

    4 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:46:05 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    New insider Palumbo John R claimed ownership of 47,857 shares (SEC Form 3)

    3 - Lucid Diagnostics Inc. (0001799011) (Issuer)

    10/7/25 4:45:33 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    Director Sparks Ronald M was granted 150,000 shares, increasing direct ownership by 231% to 215,000 units (SEC Form 4)

    4 - PAVmed Inc. (0001624326) (Issuer)

    10/2/25 4:22:08 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Leadership Updates

    Live Leadership Updates

    View All

    Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors

    Growth-focused healthcare executive brings 40 years of executive leadership experience across multiple industry sectors NEW YORK, Sept. 25, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ: PAVM), today announced the appointment of accomplished healthcare executive John R. Palumbo to its Board of Directors, effective September 22, 2025. "John is a highly accomplished executive whose 40 years of healthcare leadership experience spans earl

    9/25/25 8:01:00 AM ET
    $LUCD
    $MDRX
    $PAVM
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs

    Scelfo to strengthen and scale Lucid's market access infrastructure ahead of key upcoming reimbursement milestones—including Medicare coverage for EsoGuard—and to accelerate commercial coverage expansion NEW YORK, Sept. 16, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the appointment of Danielle Scelfo as Senior Vice President, Market Access & Government Affairs, reporting to the Chief Executive Officer. Ms. Scelfo is widely recognized in the diagnostics industry as an accomplished health policy leader with more than 25 years o

    9/16/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes

    NEW YORK, May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these importa

    5/27/25 7:31:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Financials

    Live finance-specific insights

    View All

    Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025

    Conference call scheduled for Monday, September 8, at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting NEW YORK, Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (NASDAQ:PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025, at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molec

    9/5/25 9:16:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 31, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ:PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, August 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., PAVmed's Chairman and Chief Executive Officer, will provide a business update including an overview of the Company's operations and growth strategy. In addition, Dennis McGrath, PAVmed's President and Chief Financial Officer, will discuss the Company's secon

    7/31/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025

    Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK, July 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced that it will host a business update conference call and webcast on Wednesday, August 13, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D., Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath, Lucid's Chief Financial Officer, will discuss the Company's second quarter 2025 fi

    7/30/25 8:01:00 AM ET
    $LUCD
    $PAVM
    Medical/Dental Instruments
    Health Care

    $LUCD
    $PAVM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Lucid Diagnostics Inc.

    SC 13D/A - Lucid Diagnostics Inc. (0001799011) (Subject)

    12/12/24 4:30:32 PM ET
    $LUCD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    11/14/24 10:02:46 AM ET
    $PAVM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by PAVmed Inc.

    SC 13G - PAVmed Inc. (0001624326) (Subject)

    9/23/24 8:46:15 PM ET
    $PAVM
    Medical/Dental Instruments
    Health Care